TLN Thallion Pharmaceuticals

Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) ("Thallion" or "Company") today
announced that it has delayed the date of its 2013 Annual General Meeting to a
date which will be no later than September 27, 2013.


Thallion had originally intended to hold its Annual General Meeting before May
31, 2013. However, as Thallion advances in its previously announced strategic
review process, management has come to appreciate that such process may likely
result in the requirement to present various matters to shareholders for
approval. Therefore, with a view to avoiding an unnecessary duplication of
expenses, Thallion has obtained court approval to delay the holding of its
Annual General Meeting to no later than September 27, 2013, thereby allowing for
the possibility of combining the Annual General Meeting with any other meeting
of shareholders that may be required as described above. A copy of such court
approval may be obtained from Thallion upon request.


About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) is a biotechnology company
developing pharmaceutical products in the areas of infectious disease and
oncology. The Company's lead clinical program Shigamabs(R) is a dual antibody
product for the treatment of Shiga toxin-producing E. coli bacterial infections
and has recently completed a Ph II clinical trial. Additional information about
Thallion can be obtained at www.thallion.com. 


Forward-Looking Statements

This press release contains certain forward-looking statements, including,
without limitation, statements containing the words "believe", "may", "plan",
"will", "estimate", "continue", "anticipate", "intend", "expect" and other
similar expressions which constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Forward-looking statements
reflect Thallion's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements involve
risks and uncertainties including, but not limited to, risks relating to the
outcome of the strategic review process. There are no assurances or guarantees
that the process will result in any transaction or, if a transaction is
undertaken, the terms or timing of such a transaction. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Thallion undertakes no obligation to publicly update
or revise any forward-looking statements either as a result of new information,
future events or otherwise, except as required by applicable Canadian securities
laws. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Thallion Pharmaceuticals Inc.
Michael Singer
Chief Financial Officer
(514) 940-3600
(514) 336-2343 (FAX)
info@thallion.com
www.thallion.com

Thallion Pharmaceuticals (TSXV:TLN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Thallion Pharmaceuticals (TSXV:TLN)
Historical Stock Chart
From Jul 2023 to Jul 2024